FDA grants double accelerated approval of trastuzmab deruxtecan (Enhertu)
FDA granted accelerated approval of trastuzumab deruxtecan (Enhertu) for patients with HER2-low breast cancer and HER2-mutant lung cancer based on international trials.
FDA granted accelerated approval of trastuzumab deruxtecan (Enhertu) for patients with HER2-low breast cancer and HER2-mutant lung cancer based on international trials.
Biden reignites the Cancer Moonshot, setting ambitious goals: to reduce the death rate from cancer by at least 50 percent over the next 25 years
In 2021, the International Cancer Coalition officially launched at the Bloomberg New Economy Forum in Singapore.
The 2021 Forbes China Healthcare Summit was held to discuss the theme of “Advance the Global Fight Against Cancer and Achieve a Moonshot in the Post-Pandemic Era.”
A pandemic-era CodeBreaK100 international trial led to FDA accelerated approval of sotorasib (Lumakras), the first targeted drug against KRAS, the commonest oncogene driver in human cancers which was previously thought to be uncurable.
The Bloomberg New Economy Forum convened a special “Moonshot Roundtable” gathering CEOs from major global biopharmaceuticals, leading academic physicians, and top government regulators including FDA’s Oncology Center of Excellence.
Forbes China Healthcare Summit launched, bringing together leading academic, industry, and government stakeholders in the U.S. and China to collaborate on international clinical trials in the COVID-19 pandemic era.
Bloomberg New Economy Forum in Beijing convened the first U.S.-China Task Force and recommended multi-stakeholder collaboration on international cancer clinical trials.
The U.S. FDA initiated Project Orbis to provide a framework for the submission and review of oncology products among international government regulatory agencies, with Australia and Canada as the first...